

Pain Pathways Made Simple

David M Glick, DC, DAAPM, CPE

Disclosures

Nothing to Disclose



Learning Objectives

- Differentiate between nociceptive and neuropathic pain
- Describe the process of pain transmission
- Identify the specific pain pathways that can be acted upon by pharmacotherapy and nonpharmacologic treatments



Classification of Pain

Good pain vs. Bad Pain



Clinical Pearl



Good Pain

Nociceptive Pain: Purposeful Pain

- Eudynia being pain linked to normal tissue function or damage
- -Non-maldynic Pain
- -Adaptive



Bad Pain


Neuropathic Pain: Non-purposeful Pain

- Maldynia pain linked to disorder, illness or damage
- -i.e may be abnormal, unfamiliar pain, assumed to be caused by dysfunction in PNS or CNS



Pain Mechanisms








Adapted from Nature Reviews – Neuroscience, Stephen McMahon & David Bennett, 2007.

General Anatomy of Pain





 Adapted from Von Hehn CA, Baron R, Woolf CJ. Deconstructing the neuropathic pain phenotype to reveal neural mechanisms. *Neuron*. 2012; 23;73(4):638-652.


Pain Roadmap:

Peripheral and Central Nervous System Landmarks

- Physiologic process involving multiple areas of the nervous system
- Bidirectional
- Involves normal as well as pathological processes
- A sensory experience associated with affective and cognitive responses
- Dynamic (i.e. occurring in real time)
- Adapts or changes in response to function – "Neuroplasticity"

1. Gardner EP, et al. In: Kandel E, et al, eds. *Principles of Neural Science*. 4th ed. McGraw-Hill Medical; 2000; chapters 21-23.






Pathophysiologic Classification of Pain

- Nociceptive Purposeful pain
 - Somatic or visceral linked to normal tissue function or commensurate with identifiable tissue damage
- Inflammatory Pain Usually involves tissue damage
 - Localized chemical soup of inflammatory mediators
- Neuropathic Non-purposeful pain
 - May be abnormal, unfamiliar pain, probably caused by dysfunction in PNS or CNS
- Functional Pain Dysfunctional pain
 - Non-neuropathic, non-inflammatory, often ill defined

OASP. Proposed taxonomy changes 2008. http://www.iasp-pain.org/AM/Template.cfm?Section=Home&Template=/CM/ContentDisplay.cfm&ContentID=6633. Published November 2007. Accessed May


Classification of Pain



Painweek.

Adapted from: Woolf CJ. Ann Intern Med. 2004;140:441-451.

Nociceptive vs Neuropathic Pain




I. Portenoy RK, Kanner RM. In: Portenoy RK, et al, eds. Pain Management: Theory and Practice. Philadelphia, PA: FA Davis Company; 1996:4.

2. Galer BS, Dworkin RH. A Clinical Guide to Neuropathic Pain. Minneapolis, MN: McGraw-Hill Companies Inc; 2000:8-9.




Pain Pathway Steps



Painweek.

Adapted from Scholtz J, Woolf CJ, Nat Neuroscience, 2002,5:1062-1067

Transduction: Processing at Peripheral Nerve Endings



- Conversion of mechanical, thermal or chemical stimuli into an electric charge
- Involves
 - receptors activated directly by stimuli
 - injury/inflammatory
 response



Adapted from Dougherty PM, et al. Neurochemistry of somatosensory and pain processing. In: Benzon H, et al, eds. *Essentials of Pain Medicine*. Philadelphia, PA; Saunders; 2011: chapter 2.


Peripheral Sensitization

After injury, a peripheral nervous system neuron becomes abnormally sensitive to stimuli, resulting in either or both

- Decreased threshold for activation
- Increased rate of firing

Mechanism of action*


- Tissue damage releases sensitizing "soup" of cytokines & neurotransmitters
- -COX-mediated PGE2 release
 - These events are thought to be based on a number of changes at the cellular/molecular level, including changes in receptors and ion channels.





1. Baron R. Mechanisms of disease: neuropathic pain--a clinical perspective. *Nat Clin Pract Neurol*. 2006;2(2):95-106. Figure: Adapted from Dougherty PM, et al. Neurochemistry of somatosensory and pain processing. In: Benzon H, et al, eds. *Essentials of Pain Medicine*. Philadelphia, PA; Saunders; 2011: chapter 2.

How is Pain Transduced?



Nociception


Painweek.

- Mechanical
- Thermal
- Chemical

- Prostaglandins
- Leukotrienes
- Substance P
- Histamine
- Bradykinin
- Serotonin
- Hydroxyacids
- Reactive oxygen species
- Inflammatory cytokines and chemokines

Conduction

Transfer of noxious impulses from primary nociceptors to cells in the spinal cord dorsal horn along the peripheral nerve.




Primary Nociception Fibers

Aδ – Fast/First Pain
 Large diameter
 C-fibers – Slow/second pain
 Small diameter

Non- Nociception Fibers (Proprioception) Aβ – Muscle spindle, touch & kinesthesia Larger diameter, myelinated

Figure adapted from Binder A, et al. Disease mechanisms in neuropathic itch. *Nat Clin Pract Neurol.* 2008;4(6):329-333.



Primary Nociception

A-delta fibers

- Small receptive fields
- Thermal & mechanical
- Myelinated

- Rapidly conducting
 - 10-30 m/sec
- Large diameter




C-fibers

- Broad receptive fields
- Polymodal
- Unmyelinated
- Slower conducting
 - .5-2.0 m/sec
- Cross sensitized
- Small diameter



Transmission & Modulation



Painweek

Ascending nociceptive pathways Transmitting nociceptive impulses from the dorsal horn to surpaspinal targets Fast (green) Neospinalthalamic Slow (yellow) Paleospinalthalamic

Descending inhibitory tracts (blue)

Increased activation leads to a decrease in volume control of incoming nociceptive signals reaching the brain

5-HT – Serotonin - both excitatory & inhibitory* (may not lead to pain relief)

NE – **Norepinephrine** - Inhibitory


 Adapted from Von Hehn CA, Baron R, Woolf CJ. Deconstructing the neuropathic pain phenotype to reveal neural mechanisms. *Neuron*. 2012; 23;73(4):638-652.

Transmission & Modulation

Excitatory Transmitters

- Substance P
- Calcitonin gene related peptide
- Aspartate, Glutamate

- Inhibitory Transmitters (Descending Inhibitory Pathways)
 - GABA
 - Glycine
 - Somatostatin
 - a₂ agonists





Role of Neuronal Plasticity in Pain

- Nervous system changes in
 - Neuronal structure
 - Connections between neurons
 - Quantity/properties of neurotransmitters, receptors, ion channels
- Decreases body's pain inhibitory systems (Increased Pain)
- Injury, inflammation, and disease are culprits
- Produces short-term and permanent changes
- Pivotal to the development of hypersensitivity of inflammatory pain
- Enables NS to modify its function according to different conditions or demands placed upon it.



How Acute Pain Becomes Chronic

Peripheral Sensitization

- Tissue damage releases sensitizing "soup" of cytokines & neurotransmitters
- COX-mediated PGE2 release
- Sensitized nociceptors exhibiting a decreased threshold for activation & increased rate of firing
- Central Sensitization Resulting from noxious input to the spinal cord
 - Resulting in hyperalgesia, & allodynia




Definitions


Hyperalgesia

Lowered threshold to different types of noxious stimuli

Allodynia


 Painful response to what should normally be non-painful stimuli







Neuroplasticity in Pain Processing




1. Woolf CJ, Salter MW. Science. 2000;288:1765-1768.

- Basbaum AI, Jessell TM. The perception of pain. In: Kandel ER, Schwartz JH, et al. eds. Principles of Neural Science. 4th ed. New York, NY: McGraw-Hill; 2000:479.
- 3. Cervero F, Laird JMA. Pain. 1996;68:13-23.


Painweek.

Neuroplasticity in Peripheral Pain Transmission





Peripheral Sensitization





Central Sensitization

- Activation
 - "Wind up" of dorsal horn nociceptors
- Modulation
 - Excitatory/Inhibitory neurotransmitters
- Decreased central inhibition of pain transmission
 NE/5HT

Prime role in chronic pain, particularly neuropathic pain



Definitions

Wind Up

 Causes long-term changes in nociceptive neurons, which become hyperexcitable such that they respond to lower stimuli

- NMDA-type glutamate receptors play an important role in this process 1,2,3,4
- Prolonged opening of the ion channels enables greater influx of calcium and sodium across the post-synaptic membrane and greater excitation of nociceptive neurons 2,3


- 3. Dickenson AH. Brit J Anaesthesia 1995;75:193-200.
- 4. Suzuki R and Dickenson AH. Neuroreport 2000;11:R17-21.



^{1.} Kandel ER, Schwartz JH, Jessell TM, editors. Principles of Neural Science (Fourth Edition). New York: McGraw Hill (Health Professions Division). 2000;472-491.

^{2.} Millan MJ. Progress in Neurobiology 1999;57:1-164.


First Order Synapse – Dorsal Horn



NK-1 = Neurokinin 1 receptor; AMPA = alpha-amino-3-hydroxy-5-methyle 4-isoxazolepropionic acid; NMDA = N-methyl-D-aspartic acid; VGCC = voltage gated sodium channel; TrkB = tropomyosin receptor kinase B; BDNF = Brain derived neurotrophic factor; SP = substance P



Central Sensitization




Key Influences upon signal propagation

- Excitatory Neurotransmitters
 - Substance P, CGRP,
 Glutamate
- NMDA Channel Activity
 - Glutamate binding
 - Altering channel activity
- Descending inhibitory tracts
 - NE/Serotonin (5HT)
- Mu opioid receptor

NK-1 = Neurokinin 1 receptor; AMPA = alpha-amino-3-hydroxy-5-methyle 4-isoxazolepropionic acid; NMDA = N-methyl-D-aspartic acid; VGCC = voltage gated sodium channel; TrkB = tropomyosin receptor kinase B; BDNF = Brain derived neurotrophic factor; SP = substance P; CRGP = Calcitonin gene related peptide



Dorsal Horn of the Spinal Cord Serves as a Relay Station in Pain Processing ^{1,2}




GABA-ergic inhibitory interneuron Decrease glutamate availability




Adapted from 1. Baron R. Mechanisms of disease: neuropathic pain-a clinical perspective. *Nat Clin Pract Neurology.* 2006;2:95-106. 2. Woolf CJ. Pain: moving from symptom control toward mechanism-specific pharmacologic management. *Ann Int Med.* 2004;140:441-451.

Neuroplasticity: Neural Reorganization





Neuroplasticity: Cross Talk






Central Sensitization: Neuroplasticity in Spinal Cord Processing

- Definition: Altered function of neurons or synaptic activity
- Mechanisms of central sensitization may include:
 - Changes effecting glutamate / NMDA receptors activity
 - Reduced threshold for activation
 - Increased availability of Glutamate
 - Increased influx of Na⁺/Ca⁺ (receptor open longer)
 - Modulation Excitatory/Inhibitory neurotransmitters
 - Decreased tone descending inhibitory pathways²
 - Activation/migration of glial cells into the spinal cord³
 - Changes in the thalamus and primary somatosensory cortex⁴

1. Mannion RJ, Woolf CJ: *Clin J Pain.* 2000;16(3):S151-S153. 2. Ossipov MH, et al. *Ann NY Acad Sci.* 2000;909:12-24. 3. Wieseler-Frank J, et al. *Neurosignals.* 2005;14:166-174. 4. Guilbaud G, et al. *Exp Brain Res.* 1992;92:227-245.

Brain Regions Involved in Pain Processing





Common Pharmacologic Therapies


- Acetaminophen
- NSAIDS
- Antiepileptics
- TCAs
- SNRIs
- Topicals
- Muscle Relaxants
- Opioids

Cortex and subcortical regions: Perception, sensory, and affective pain components Brainstem: Descending modulation Spinal cord:

Synaptic transmission, modulation and central sensitization

Periphery: Transmission and peripheral sensitization






Adapted from Woolf C, Max M Anesthesiology 2001



Pharmacological Targets in Pain



Woolf C, Max M Anesthesiology 2001

Non-Pharmacologic Treatments Reliant Upon Pain Pathways

- Classic Neuromodulation (Implantable spinal and extraspinal)
- External devices (Transcutaneous)
 - -Quell Musculoskeletal pain (neck, back, etc.)
 - Nerivio Migra Acute migraine
 - Cefaly Acute migraine without aura
 - Livia Menstrual cramps
 - ActiPatch Musculoskeletal pain
 - ClearUP Sinus pain
 - -gammaCore Migraine & cluster HA (Covid-19 emergency use respiratory system/asthma)



The Chronic Pain Armamentarium

<u>Nonopioids</u>

- Acetaminophen
- NSAIDs
- COX-2 inhibitors


<u>Opioids</u>

Painweek


- Mu-opioid agonists
- Mixed Agonist-antagonists

Adjuvant analgesics

- Antidepressants
- Anticonvulsants
- Topical agents/local anesthetics



VA DoD Stepped Pain Care Model





PCSS-O Webinar Implementation of the National Pain Strategy and Safer Opioid Prescribing: A Military Perspective, Buckenmaier C (COL) ret, Aug 24, 2016 JAMA Intern Med. 2015;175(5):682-689. doi:10.1001/jamainternmed.2015.97

Objectives for Treating Pain

- Reduce overall signal by addressing the source
 - Treatment by eliminating the pathology
 - Mitigate the response at the source
- Interrupt or interfere with the signal within the pathway
 - Directly addressing steps in the pathway
- Reduce the overall excitatory response
- Increase the inhibitory response
- Decrease perception of the signals



Neuroplasticity Considerations

- Neuroplasticity can be a two way process, and should be considered reversable
- Can delay or slow the perceived response to pain treatment
- May play a role in amplification of pain perception in the presence of comorbidities
- Is often overlooked when caring for the patient




Case Study

- 54 year-old with three year history of neck, shoulder and upper extremity pain following a lifting injury
 - Current Medications
 - Fluoxetine
 - Milnacipran
 - Gabapentin
 - Clonazepam
 - Alprazolam
 - Methocarbamol
 - Tapentadol
 - Acetaminophen and propoxyphene
 - Zolpidem

Painweek.

- Diclofenac topical
- Acetaminophen



Importance for Understanding Pain Mechanisms

- Allow for rational rather than empirical approach to pain control
- Foster the development of diagnostic tools to identify specific pain mechanisms
- Facilitate pharmacotherapies that act on specific pain pathways and mechanisms
- Reduce the number of pharmacotherapies and incidence of drug-related adverse events (rationale polypharmacy)
- Enhances use of non-pharmacologic treatments
- Improve overall patient care and outcome
 - Tailoring treatment based on the individual patient and pain type
- Do not forget to look for the spear

